David A Dodd bought $20k of GOVX
President, CEO at GeoVax Labs, Inc.. 8,729 shares at an average of $2.27, traded Feb 21, 2024, filed Feb 22, 2024.
Score components
- +25RoleCEO
- 0Trade size$20k at market
- +10Relative to holdingsHoldings up 88%
- +18Price context0% above the 52-week low; 82% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-24-005209, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 21, 2024 | POpen-market purchase Common Stock | +520 | $2.15 | $1,118 | 10,452 | Feb 22, 2024 |
| Feb 22, 2024 | POpen-market purchase Common Stock | +8,209 | $2.27 | $19k | 18,661 | Feb 22, 2024 |
Related signals
Other insiders at GeoVax Labs, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | GOVXbuy GeoVax Labs, Inc. | John N Spencer Jr director | $5,498 10,000 shares | +88% | |
| 29Weak | GOVXbuy GeoVax Labs, Inc. | Kelly T. McKee Jr. Chief Medical Officer | $742 1,107 shares | +46% | |
| 58Moderate | GeoVax Labs, Inc. | John N Spencer Jr director | $9,800 10,000 shares | +713% | |
| 58Moderate | GeoVax Labs, Inc. | John W. Sharkey VP, Business Development | $5,940 6,000 shares | +3141% | |
| 64Notable | GeoVax Labs, Inc. | David A Dodd President, CEO | $11k 10,000 shares | +38% | |
| 65Notable | GeoVax Labs, Inc. | Mark Reynolds CFO | $7,343 6,800 shares | +94% | |
| 39Weak | GOVXbuy GeoVax Labs, Inc. | David A Dodd President, CEO | $16k 8,000 shares | +43% | |
| 54Moderate | GeoVax Labs, Inc. | Mark Reynolds CFO | $5,540 2,000 shares | +38% | |
| 29Weak | GOVXbuy GeoVax Labs, Inc. | Kelly T. McKee Jr. Chief Medical Officer | $2,500 6,944 shares | +24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.